Trajan : 1H FY22 Financial Results Investor Presentation

ersonal use only

1H FY22 Trading Update

Stephen Tomisich

CEO and Managing Director

24th February 2022

Science that benefits people

only	Respect
use	Integrity
ersonal	Discipline

Empowerment

Through our values and actions, we aim to impact human wellbeing in a meaningful way.

Science that benefits people

1H FY22 Highlights

Science that benefits people

Underlying revenue growth, EBITDA in line with plan

only	$43.7M	20.6%1	$4.8M	2.1 %
	Gross Profit
use	Total	Revenue	Normalised	Margin
Revenue	Growth	EBITDA	Expansion2
ersonal
	•	Both business segments contributed growth.
		•	Organic growth of 12.8% on a constant currency basis.
		•	Normalised 1H FY22 EBITDA in line with expectation.
		•	Gross margin improvement driven by scale and efficiency benefits.
		1.	Constant currency basis over PCP.
		2.	Over PCP.

3

Full Year FY22 Forecast Guidance

Science that benefits people

only	$104.0M	$12.5M
ersonal use
to	to
$110.0M	$13.5M
Total Revenue	Normalised
range	EBITDA range

• Organic growth forecast at high single digit rate in 2H FY22.
• Contributions from acquisitions to step up in 2H FY22.
• Forecasting relatively broad revenue and normalised EBITDA ranges driven by the recent acquisitions and emerging technology sales growth.

4

ersonal use only

1H FY22 Operational Update

Science that benefits people